UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (740) 740
humans (739) 739
life sciences & biomedicine (682) 682
animals (428) 428
class i phosphatidylinositol 3-kinases (374) 374
oncology (352) 352
female (333) 333
phosphatidylinositol 3-kinases - genetics (322) 322
phosphatidylinositol 3-kinases - antagonists & inhibitors (320) 320
mice (307) 307
phosphatidylinositol 3-kinases - metabolism (279) 279
cell line, tumor (271) 271
mutation (242) 242
male (187) 187
signal transduction (183) 183
class i phosphatidylinositol 3-kinases - antagonists & inhibitors (179) 179
protein kinase inhibitors - pharmacology (163) 163
cell biology (155) 155
antineoplastic agents - pharmacology (153) 153
signal transduction - drug effects (149) 149
middle aged (146) 146
proto-oncogene proteins c-akt - metabolism (134) 134
cancer (133) 133
enzyme inhibitors - pharmacology (126) 126
phosphorylation (126) 126
aged (125) 125
class i phosphatidylinositol 3-kinases - metabolism (122) 122
kinases (121) 121
class i phosphatidylinositol 3-kinases - genetics (116) 116
adult (115) 115
biochemistry & molecular biology (115) 115
cell proliferation - drug effects (109) 109
antineoplastic agents - therapeutic use (96) 96
apoptosis - drug effects (87) 87
xenograft model antitumor assays (85) 85
tor serine-threonine kinases - antagonists & inhibitors (84) 84
cells, cultured (81) 81
pi3k (81) 81
apoptosis (79) 79
tumors (79) 79
1-phosphatidylinositol 3-kinase (77) 77
morpholines - pharmacology (77) 77
breast neoplasms - drug therapy (76) 76
research article (75) 75
proteins (74) 74
breast neoplasms - genetics (72) 72
genetic aspects (70) 70
abridged index medicus (68) 68
neoplasms (68) 68
immunology (67) 67
aged, 80 and over (66) 66
dose-response relationship, drug (65) 65
mice, knockout (65) 65
pharmacology & pharmacy (65) 65
pten phosphohydrolase - genetics (64) 64
treatment outcome (64) 64
class ib phosphatidylinositol 3-kinase (63) 63
isoenzymes - antagonists & inhibitors (63) 63
research (63) 63
tor serine-threonine kinases - metabolism (63) 63
breast cancer (62) 62
mice, nude (62) 62
protein kinase inhibitors - therapeutic use (62) 62
molecular targeted therapy (61) 61
proto-oncogene proteins - genetics (61) 61
colorectal neoplasms - genetics (60) 60
gene expression (60) 60
mice, inbred c57bl (59) 59
proto-oncogene proteins c-akt - antagonists & inhibitors (58) 58
science & technology - other topics (58) 58
phosphatidylinositol 3-kinases - physiology (57) 57
medicine (56) 56
multidisciplinary sciences (56) 56
pik3ca (56) 56
proto-oncogene proteins b-raf - genetics (56) 56
analysis (55) 55
ras proteins - genetics (55) 55
receptor, epidermal growth factor - antagonists & inhibitors (55) 55
breast neoplasms - pathology (54) 54
prognosis (54) 54
cell proliferation (53) 53
hematology (53) 53
proto-oncogene proteins p21 (53) 53
chromones - pharmacology (52) 52
colorectal neoplasms - drug therapy (52) 52
pyrimidines - pharmacology (52) 52
care and treatment (51) 51
drug resistance, neoplasm - genetics (51) 51
neoplasms - drug therapy (51) 51
autophagy (48) 48
quinazolines - pharmacology (48) 48
drug resistance, neoplasm (47) 47
akt protein (46) 46
inhibitors (46) 46
phosphorylation - drug effects (46) 46
cell line (45) 45
colorectal cancer (45) 45
isoenzymes - metabolism (45) 45
rna interference (45) 45
cell survival - drug effects (44) 44
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature (London), ISSN 1476-4687, 02/2017, Volume 542, Issue 7642, pp. 489 - 493
.... The phosphatidylinositol 3-kinase delta (PI3K delta) pathway regulates AID by suppressing its expression in B cells4... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Isoquinolines - adverse effects | Class I Phosphatidylinositol 3-Kinases - metabolism | Humans | Lymphoma, Mantle-Cell - pathology | Phosphatidylinositol 3-Kinases - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Translocation, Genetic - drug effects | Isoquinolines - pharmacology | Antineoplastic Agents - adverse effects | Genomic Instability - drug effects | Female | Antineoplastic Agents - pharmacology | Purines - adverse effects | B-Lymphocytes - pathology | Immunoglobulin Class Switching - drug effects | Somatic Hypermutation, Immunoglobulin - drug effects | Lymphoma, Mantle-Cell - genetics | B-Lymphocytes - metabolism | Quinazolinones - pharmacology | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Enzyme Inhibitors - adverse effects | B-Lymphocytes - enzymology | Purines - pharmacology | Enzyme Inhibitors - pharmacology | Pyrimidines - pharmacology | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | B-Lymphocytes - drug effects | Animals | Agammaglobulinaemia Tyrosine Kinase | Cytidine Deaminase - metabolism | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Immunoglobulin Heavy Chains - genetics | Quinazolinones - adverse effects | Recombination, Genetic - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Frontiers in immunology, ISSN 1664-3224, 02/2018, Volume 9, pp. 237 - 237
The phosphatidylinositol-3-kinase (PI3K)/Akt pathway is important for multiple stages of herpesvirus replication including virus entry, replication, latency,... 
APDS | Cytomegalovirus | Phosphatidylinositol-3-kinase | PASLI | PIK3CD | Epstein-Barr virus | Akt | PIK3R1 | Life Sciences & Biomedicine | Immunology | Science & Technology | Class I Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Cytomegalovirus Infections - immunology | Phosphatidylinositol 3-Kinases - metabolism | Class I Phosphatidylinositol 3-Kinases - immunology | Cytomegalovirus Infections - genetics | Phosphatidylinositol 3-Kinases - immunology | Herpesvirus 4, Human - isolation & purification | T-Lymphocytes - metabolism | Cytomegalovirus Infections - virology | Epstein-Barr Virus Infections - genetics | Class I Phosphatidylinositol 3-Kinases - drug effects | Gain of Function Mutation | Immunologic Deficiency Syndromes - immunology | Proto-Oncogene Proteins c-akt - metabolism | Immunosuppressive Agents - pharmacology | Cytomegalovirus - isolation & purification | Genetic Predisposition to Disease | Epstein-Barr Virus Infections - virology | Epstein-Barr Virus Infections - immunology | Herpesvirus 4, Human - immunology | Viremia - genetics | Viremia - drug therapy | Immunologic Deficiency Syndromes - virology | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Epstein-Barr Virus Infections - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Cytomegalovirus - immunology | Proto-Oncogene Proteins c-akt - immunology | Viremia - virology | Cytomegalovirus Infections - drug therapy | Immunologic Deficiency Syndromes - genetics | T-Lymphocytes - immunology | Viremia - immunology | Index Medicus | phosphatidylinositol-3-kinase
Journal Article
Blood, ISSN 1528-0020, 03/2013, Volume 121, Issue 12, pp. 2274 - 2284
The increased expression of PI3K p110α in mantle cell lymphoma, particularly at relapse, suggests a role for p110α in disease progression. A high PIK3CA/PIK3CD... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Recurrence | Humans | Lymphoma, Mantle-Cell - pathology | Quinazolinones - administration & dosage | Substrate Specificity | Phosphatidylinositol 3-Kinases - metabolism | Gene Expression Regulation, Enzymologic - physiology | Purines - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | DNA Mutational Analysis | Purines - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Gene Expression Regulation, Neoplastic - physiology | Lymphoma, Mantle-Cell - genetics | Lymphoma, Mantle-Cell - metabolism | Gene Expression Regulation, Neoplastic - genetics | Quinazolinones - pharmacology | Purines - pharmacology | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Phosphatidylinositol 3-Kinases - genetics | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Class I Phosphatidylinositol 3-Kinases | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Quinazolinones - therapeutic use | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 10/2009, Volume 101, Issue 19, pp. 1308 - 1324
The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth factor receptor (EGFR) have expanded the range of treatment options for... 
Life Sciences & Biomedicine | Oncology | Science & Technology | PTEN Phosphohydrolase - drug effects | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Colorectal Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - drug effects | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cetuximab | Odds Ratio | PTEN Phosphohydrolase - genetics | Proto-Oncogene Proteins - drug effects | Antibodies, Monoclonal - pharmacology | Proto-Oncogene Proteins - genetics | Randomized Controlled Trials as Topic | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins p21(ras) - drug effects | Animals | Class I Phosphatidylinositol 3-Kinases | Mutation - drug effects | Proto-Oncogene Proteins B-raf - drug effects | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Colorectal Neoplasms - pathology | Neoplasm Staging | Research Design | Usage | Care and treatment | Prognosis | Gene mutations | Colorectal cancer | Monoclonal antibodies | Development and progression | Genetic aspects | Research | Biological markers | Health aspects | Biomarkers | Cancer therapies | Clinical outcomes | Index Medicus | Review
Journal Article
Blood, ISSN 1528-0020, 11/2017, Volume 130, Issue 21, pp. 2307 - 2316
Journal Article